News & Updates

The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.

Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.

A short-course induction chemotherapy conducted prior to chemoradiotherapy appears to deliver significant survival boost in locally advanced cervical cancer, according to the phase III GCIG INTERLACE trial.